

Transaction Contacts

<u>Coverage Team:</u> Gabriel Cavazos Brian Swanson ECM Team: Jack Bannister

Oculis

\$40 Million Follow-On Offering

SVD Securities Joint Bookrunner May 2023

SVB Securities Serves as Joint Bookrunner for Oculis Holding AG's (Nasdaq: OCS) \$40 Million Follow-On Offering

Key Transaction Highlights

- Publicly launched May 30th pre-open and priced May 31st post-close
- Deal consisted of 3,500,000 ordinary shares sold at a public offering price of \$11.50 per share representing the last sale price.
- Oculis intends to use the net proceeds from this offering, together with its existing resources, to fund its development programs in Diabetic Macular Edema and other ophthalmic indications, and for working capital and general corporate purposes.
- This is SVB Securities' 1st bookrun offering for Oculis after having served as capital markets advisor on its de-SPAC merger in March 2023. This is also SVB Securities' 25th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click here. If you would like to unsubscribe from all SVB Securities distributions, click here.

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON 53 State Street 40th Floor Boston, MA 02109 CHARLOTTE 2151 Hawkins Street Suite 1025 Charlotte, NC 28203 NASHVILLE 40 Burton Hills Boulevard Suite 200 Nashville, TN 37215

NEW YORK 1301 Avenue of the Americas 12th Floor New York, NY 10019 SAN FRANCISCO 255 California Street 12th Floor San Francisco, CA 94111

> An SVB Company svbsecurities.com